180 related articles for article (PubMed ID: 37381778)
21. Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis.
Karimi-Farsijani S; Pfeiffer PB; Banerjee S; Baur J; Kuhn L; Kupfer N; Hegenbart U; Schönland SO; Wiese S; Haupt C; Schmidt M; Fändrich M
Nat Commun; 2024 Jun; 15(1):5121. PubMed ID: 38879609
[TBL] [Abstract][Full Text] [Related]
22. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation.
Mazzini G; Ricagno S; Caminito S; Rognoni P; Milani P; Nuvolone M; Basset M; Foli A; Russo R; Merlini G; Palladini G; Lavatelli F
FEBS J; 2022 Jan; 289(2):494-506. PubMed ID: 34482629
[TBL] [Abstract][Full Text] [Related]
23. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
Vaxman I; Dispenzieri A; Muchtar E; Gertz M
Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
[TBL] [Abstract][Full Text] [Related]
24. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
Zhang C; Huang X; Li J
Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
[TBL] [Abstract][Full Text] [Related]
25. Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies.
Dasari S; Theis JD; Vrana JA; Meureta OM; Quint PS; Muppa P; Zenka RM; Tschumper RC; Jelinek DF; Davila JI; Sarangi V; Kurtin PJ; Dogan A
J Proteome Res; 2015 Apr; 14(4):1957-67. PubMed ID: 25734799
[TBL] [Abstract][Full Text] [Related]
26. Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage.
Lin Y; Marin-Argany M; Dick CJ; Redhage KR; Blancas-Mejia LM; Bulur P; Butler GW; Deeds MC; Madden BJ; Williams A; Wall JS; Dietz A; Ramirez-Alvarado M
Cytotherapy; 2017 Dec; 19(12):1426-1437. PubMed ID: 29037943
[TBL] [Abstract][Full Text] [Related]
27. Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics.
Rognoni P; Mazzini G; Caminito S; Palladini G; Lavatelli F
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577839
[TBL] [Abstract][Full Text] [Related]
28. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.
Arendt BK; Ramirez-Alvarado M; Sikkink LA; Keats JJ; Ahmann GJ; Dispenzieri A; Fonseca R; Ketterling RP; Knudson RA; Mulvihill EM; Tschumper RC; Wu X; Zeldenrust SR; Jelinek DF
Blood; 2008 Sep; 112(5):1931-41. PubMed ID: 18567838
[TBL] [Abstract][Full Text] [Related]
29. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
Weiss BM; Wong SW; Comenzo RL
Blood; 2016 May; 127(19):2275-80. PubMed ID: 26907632
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of plasma cell and lymphoproliferative disorders among blood relatives of patients with light chain amyloidosis.
Staron A; Verma K; Sanchorawala V
Br J Haematol; 2022 Sep; 198(5):861-865. PubMed ID: 35499208
[TBL] [Abstract][Full Text] [Related]
31. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
[TBL] [Abstract][Full Text] [Related]
33. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
Morgan GJ; Kelly JW
J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers in Immunoglobulin Light Chain Amyloidosis.
Kufová Z; Sevcikova T; Growkova K; Vojta P; Filipová J; Adam Z; Pour L; Penka M; Rysava R; Němec P; Brozova L; Vychytilova P; Jurczyszyn A; Grosicki S; Barchnicka A; Hajdúch M; Simicek M; Hájek R
Klin Onkol; 2017; 30(Supplementum2):60-67. PubMed ID: 28903572
[TBL] [Abstract][Full Text] [Related]
35. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
Koike H; Katsuno M
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
[TBL] [Abstract][Full Text] [Related]
36. Amyloid formation in light chain amyloidosis.
Ramirez-Alvarado M
Curr Top Med Chem; 2012; 12(22):2523-33. PubMed ID: 23339305
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis and management of systemic light chain AL amyloidosis.
Bhutani D; Lentzsch S
Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
[TBL] [Abstract][Full Text] [Related]
38. Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.
Granzow M; Hegenbart U; Hinderhofer K; Hose D; Seckinger A; Bochtler T; Hemminki K; Goldschmidt H; Schönland SO; Jauch A
Haematologica; 2017 Jul; 102(7):1281-1290. PubMed ID: 28341732
[TBL] [Abstract][Full Text] [Related]
39. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity.
Guan J; Mishra S; Shi J; Plovie E; Qiu Y; Cao X; Gianni D; Jiang B; Del Monte F; Connors LH; Seldin DC; Lavatelli F; Rognoni P; Palladini G; Merlini G; Falk RH; Semigran MJ; Dec GW; Macrae CA; Liao R
Basic Res Cardiol; 2013 Sep; 108(5):378. PubMed ID: 23982491
[TBL] [Abstract][Full Text] [Related]
40. Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.
Oberti L; Rognoni P; Barbiroli A; Lavatelli F; Russo R; Maritan M; Palladini G; Bolognesi M; Merlini G; Ricagno S
Sci Rep; 2017 Dec; 7(1):16809. PubMed ID: 29196671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
